Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for ALLO
| Stock Name | Allogene Therapeutics Inc |
| Ticker | ALLO(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US0197701065 |
Show aggregate ALLO holdings
News associated with ALLO
- Analysts Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $8.44
- Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages […] - 2025-09-08 02:18:43
- Mitsubishi UFJ Asset Management Co. Ltd. Grows Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
- Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 4.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 264,065 shares of the company’s stock after buying an additional 10,489 shares during the quarter. Mitsubishi UFJ […] - 2025-08-14 05:33:06
- Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $8.44
- Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average […] - 2025-08-14 02:15:04
- Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of “Moderate Buy” by Analysts
- Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month […] - 2025-07-17 05:10:53
- Vontobel Holding Ltd. Decreases Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
- Vontobel Holding Ltd. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 5.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 185,646 shares of the company’s stock after selling 9,811 shares during the period. Vontobel Holding Ltd.’s holdings in Allogene Therapeutics were worth $271,000 as of its most […] - 2025-07-09 05:02:59
- Exchange Traded Concepts LLC Purchases 8,183 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)
- Exchange Traded Concepts LLC lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 13.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 68,858 shares of the company’s stock after purchasing an additional 8,183 shares during the period. […] - 2025-06-25 04:58:50
- Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Price Target at $8.44
- Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average […] - 2025-06-25 02:12:49
- Ameriprise Financial Inc. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
- Ameriprise Financial Inc. lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 14.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 201,943 shares of the company’s stock after acquiring an additional 24,830 shares during the quarter. Ameriprise Financial Inc.’s holdings in Allogene Therapeutics were worth $430,000 as of its […] - 2025-06-05 04:22:51
- Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Lowered by Citizens Jmp
- Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) was downgraded by research analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday, Marketbeat reports. A number of other brokerages have also recently commented on ALLO. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 […] - 2025-05-16 02:35:02
- Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $7.00 at Piper Sandler
- Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) had its price target decreased by Piper Sandler from $9.00 to $7.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. ALLO has been the subject of a number of other reports. Robert W. Baird decreased their target price on […] - 2025-05-16 02:34:58
- Dimensional Fund Advisors LP Grows Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
- Dimensional Fund Advisors LP raised its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 30.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,561,626 shares of the company’s stock after purchasing an additional 831,146 shares during the quarter. Dimensional Fund Advisors […] - 2025-05-12 05:22:49
- Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29
- Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price […] - 2025-05-06 02:09:01
- Legal & General Group Plc Decreases Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
- Legal & General Group Plc trimmed its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 11.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 112,235 shares of the company’s stock after selling 15,172 shares during the quarter. Legal & General Group Plc’s holdings in Allogene Therapeutics were worth $239,000 at the end […] - 2025-05-01 04:57:03
- Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Vanguard Group Inc.
- Vanguard Group Inc. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 3.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,000,692 shares of the company’s stock after selling 327,007 shares during the period. Vanguard Group Inc.’s holdings in Allogene Therapeutics were worth $17,041,000 at the end […] - 2025-04-17 04:22:52
- Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29
- Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among […] - 2025-04-11 02:40:54
- Allogene's ALLO-329 Granted Three FDA Fast Track Designations
- (RTTNews) - Clinical-stage biotechnology company Allogene Therapeutics, Inc. (ALLO), Monday announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast Track Designations (FTD) from the U.S. Food and Drug Administration (FDA) for - 2025-04-07 12:57:11
- Teacher Retirement System of Texas Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
- Teacher Retirement System of Texas raised its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 28.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 43,877 shares of the company’s stock after purchasing an additional 9,839 shares during the quarter. Teacher Retirement System of Texas’ holdings in Allogene Therapeutics were worth $93,000 […] - 2025-04-03 04:16:48
- Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 16.2% in February
- Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 39,100,000 shares, a growth of 16.2% from the February 13th total of 33,660,000 shares. Based on an average daily trading volume, of 5,120,000 […] - 2025-03-21 04:58:44
- Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $8.00 at HC Wainwright
- Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price objective decreased by HC Wainwright from $9.00 to $8.00 in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating […] - 2025-03-20 05:44:59
- Head to Head Analysis: Allogene Therapeutics (NASDAQ:ALLO) and DBV Technologies (NASDAQ:DBVT)
- Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations. Analyst Ratings This is a breakdown of […] - 2025-02-24 04:14:49
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ALLO holdings
| Date | Number of ALLO Shares Held | Base Market Value of ALLO Shares | Local Market Value of ALLO Shares | Change in ALLO Shares Held | Change in ALLO Base Value | Current Price per ALLO Share Held | Previous Price per ALLO Share Held |
|---|
| 2025-12-03 (Wednesday) | 152,957 | USD 232,495 | USD 232,495 | 0 | USD 27,533 | USD 1.52 | USD 1.34 |
| 2025-12-02 (Tuesday) | 152,957 | USD 204,962 | USD 204,962 | 5,700 | USD 3,220 | USD 1.34 | USD 1.37 |
| 2025-12-01 (Monday) | 147,257 | USD 201,742 | USD 201,742 | 0 | USD -13,253 | USD 1.37 | USD 1.46 |
| 2025-11-28 (Friday) | 147,257 | USD 214,995 | USD 214,995 | 380 | USD 6,430 | USD 1.46 | USD 1.42 |
| 2025-11-27 (Thursday) | 146,877 | USD 208,565 | USD 208,565 | 0 | USD 0 | USD 1.42 | USD 1.42 |
| 2025-11-26 (Wednesday) | 146,877 | USD 208,565 | USD 208,565 | 1,140 | USD 10,363 | USD 1.42 | USD 1.36 |
| 2025-11-25 (Tuesday) | 145,737 | USD 198,202 | USD 198,202 | 1,900 | USD 4,022 | USD 1.36 | USD 1.35 |
| 2025-11-24 (Monday) | 143,837 | USD 194,180 | USD 194,180 | 380 | USD 17,728 | USD 1.35 | USD 1.23 |
| 2025-11-21 (Friday) | 143,457 | USD 176,452 | USD 176,452 | 0 | USD -1,435 | USD 1.23 | USD 1.24 |
| 2025-11-20 (Thursday) | 143,457 | USD 177,887 | USD 177,887 | -1,508 | USD -4,769 | USD 1.24 | USD 1.26 |
| 2025-11-19 (Wednesday) | 144,965 | USD 182,656 | USD 182,656 | 375 | USD -6,757 | USD 1.26 | USD 1.31 |
| 2025-11-18 (Tuesday) | 144,590 | USD 189,413 | USD 189,413 | 2,256 | USD 14,342 | USD 1.31 | USD 1.23 |
| 2025-11-17 (Monday) | 142,334 | USD 175,071 | USD 175,071 | 754 | USD 928 | USD 1.23 | USD 1.23 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ALLO by Blackrock for IE00BYXG2H39
Show aggregate share trades of ALLO| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-12-02 | BUY | 5,700 | 1.380 | 1.300 | 1.308 | USD 7,456 | 1.61 |
| 2025-11-28 | BUY | 380 | 1.490 | 1.410 | 1.418 | USD 539 | 1.62 |
| 2025-11-26 | BUY | 1,140 | 1.430 | 1.310 | 1.322 | USD 1,507 | 1.62 |
| 2025-11-26 | BUY | 1,140 | 1.430 | 1.310 | 1.322 | USD 1,507 | 1.62 |
| 2025-11-25 | BUY | 1,900 | 1.400 | 1.300 | 1.310 | USD 2,489 | 1.62 |
| 2025-11-24 | BUY | 380 | 1.350 | 1.220 | 1.233 | USD 469 | 1.62 |
| 2025-11-20 | SELL | -1,508 | 1.330 | 1.220 | 1.231 | USD -1,856 | 1.62 Profit of 594 on sale |
| 2025-11-19 | BUY | 375 | 1.350 | 1.230 | 1.242 | USD 466 | 1.63 |
| 2025-11-18 | BUY | 2,256 | 1.310 | 1.220 | 1.229 | USD 2,773 | 1.63 |
| 2025-11-17 | BUY | 754 | 1.280 | 1.210 | 1.217 | USD 918 | 1.63 |
| 2025-11-14 | BUY | 377 | 1.250 | 1.160 | 1.169 | USD 441 | 1.63 |
| 2025-11-12 | BUY | 376 | 1.270 | 1.205 | 1.212 | USD 456 | 1.64 |
| 2025-11-10 | BUY | 374 | 1.230 | 1.160 | 1.167 | USD 437 | 1.64 |
| 2025-11-06 | BUY | 376 | 1.100 | 1.050 | 1.055 | USD 397 | 1.65 |
| 2025-11-04 | BUY | 377 | 1.170 | 1.050 | 1.062 | USD 400 | 1.65 |
| 2025-10-30 | BUY | 1,890 | 1.260 | 1.210 | 1.215 | USD 2,296 | 1.66 |
| 2025-10-29 | BUY | 754 | 1.220 | 1.280 | 1.274 | USD 961 | 1.66 |
| 2025-10-22 | SELL | -1,484 | 1.210 | 1.270 | 1.264 | USD -1,876 | 1.67 Profit of 606 on sale |
| 2025-10-20 | BUY | 742 | 1.290 | 1.330 | 1.326 | USD 984 | 1.68 |
| 2025-10-17 | BUY | 1,849 | 1.230 | 1.270 | 1.266 | USD 2,341 | 1.68 |
| 2025-10-15 | BUY | 2,928 | 1.270 | 1.300 | 1.297 | USD 3,798 | 1.68 |
| 2025-10-03 | BUY | 2,646 | 1.330 | 1.340 | 1.339 | USD 3,543 | 1.69 |
| 2025-10-02 | BUY | 378 | 1.290 | 1.290 | 1.290 | USD 488 | 1.69 |
| 2025-09-30 | BUY | 752 | 1.240 | 1.310 | 1.303 | USD 980 | 1.69 |
| 2025-09-26 | BUY | 752 | 1.250 | 1.260 | 1.259 | USD 947 | 1.70 |
| 2025-09-25 | BUY | 752 | 1.200 | 1.220 | 1.218 | USD 916 | 1.70 |
| 2025-09-24 | BUY | 1 | 1.230 | 1.230 | 1.230 | USD 1 | 1.70 |
| 2025-09-18 | BUY | 375 | 1.210 | 1.230 | 1.228 | USD 461 | 1.71 |
| 2025-09-17 | BUY | 1,128 | 1.130 | 1.200 | 1.193 | USD 1,346 | 1.71 |
| 2025-08-20 | SELL | -1,504 | 1.060 | 1.080 | 1.078 | USD -1,621 | 1.72 Profit of 972 on sale |
| 2025-07-30 | BUY | 1,468 | 1.290 | 1.500 | 1.479 | USD 2,171 | 1.75 |
| 2025-07-17 | SELL | -740 | 1.240 | 1.270 | 1.267 | USD -938 | 1.77 Profit of 370 on sale |
| 2025-07-11 | SELL | -3,008 | 1.280 | 1.330 | 1.325 | USD -3,986 | 1.78 Profit of 1,370 on sale |
| 2025-07-07 | BUY | 1,128 | 1.160 | 1.230 | 1.223 | USD 1,380 | 1.80 |
| 2025-07-02 | BUY | 20,570 | 1.200 | 1.290 | 1.281 | USD 26,350 | 1.80 |
| 2025-06-11 | BUY | 748 | 1.450 | 1.500 | 1.495 | USD 1,118 | 1.83 |
| 2025-06-10 | BUY | 746 | 1.460 | 1.510 | 1.505 | USD 1,123 | 1.84 |
| 2025-06-04 | SELL | -374 | 1.290 | 1.360 | 1.353 | USD -506 | 1.85 Profit of 186 on sale |
| 2025-04-23 | BUY | 373 | 1.610 | 1.750 | 1.736 | USD 648 | 2.02 |
| 2025-04-10 | SELL | -2,976 | 1.370 | 1.450 | 1.442 | USD -4,291 | 2.08 Profit of 1,907 on sale |
| 2025-04-08 | SELL | -372 | 1.360 | 1.570 | 1.549 | USD -576 | 2.10 Profit of 204 on sale |
| 2025-04-07 | SELL | -372 | 1.430 | 1.500 | 1.493 | USD -555 | 2.11 Profit of 228 on sale |
| 2025-04-04 | SELL | -1,870 | 1.440 | 1.460 | 1.458 | USD -2,726 | 2.11 Profit of 1,227 on sale |
| 2025-04-01 | BUY | 1,496 | 1.370 | 1.450 | 1.442 | USD 2,157 | 2.13 |
| 2025-03-31 | SELL | -1,122 | 1.460 | 1.500 | 1.496 | USD -1,679 | 2.14 Profit of 722 on sale |
| 2025-03-21 | BUY | 12,438 | 1.620 | 1.640 | 1.638 | USD 20,373 | 2.18 |
| 2025-03-14 | SELL | -5,312 | 1.940 | 2.100 | 2.084 | USD -11,070 | 2.21 Profit of 681 on sale |
| 2025-03-07 | SELL | -664 | 2.180 | 2.320 | 2.306 | USD -1,531 | 2.23 Loss of -54 on sale |
| 2025-03-04 | SELL | -332 | 1.900 | 1.920 | 1.918 | USD -637 | 2.24 Profit of 106 on sale |
| 2025-02-25 | BUY | 664 | 1.990 | 2.150 | 2.134 | USD 1,417 | 2.26 |
| 2025-02-19 | SELL | -329 | 2.600 | 3.780 | 3.662 | USD -1,205 | 2.26 Loss of -461 on sale |
| 2025-02-13 | BUY | 993 | 1.410 | 1.440 | 1.437 | USD 1,427 | 2.28 |
| 2025-02-12 | BUY | 331 | 1.430 | 1.460 | 1.457 | USD 482 | 2.29 |
| 2025-02-11 | BUY | 1,324 | 1.400 | 1.480 | 1.472 | USD 1,949 | 2.31 |
| 2024-12-30 | SELL | -14,492 | 2.100 | 2.170 | 2.163 | USD -31,346 | 2.54 Profit of 5,496 on sale |
| 2024-11-18 | SELL | -5,493 | 2.150 | 2.320 | 2.303 | USD -12,650 | 2.82 Profit of 2,821 on sale |
| 2024-11-08 | SELL | -365 | 3.080 | 3.260 | 3.242 | USD -1,183 | 2.80 Loss of -163 on sale |
| 2024-10-21 | SELL | -370 | 2.800 | 2.900 | 2.890 | USD -1,069 | 0.00 Loss of -1,069 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ALLO
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 274,845 | 0 | 1,413,156 | 19.4% |
| 2025-09-18 | 599,122 | 27,154 | 3,610,617 | 16.6% |
| 2025-09-17 | 472,488 | 4,000 | 1,678,164 | 28.2% |
| 2025-09-16 | 224,258 | 515 | 1,308,457 | 17.1% |
| 2025-09-15 | 182,586 | 4,333 | 859,181 | 21.3% |
| 2025-09-12 | 247,120 | 0 | 783,377 | 31.5% |
| 2025-09-11 | 201,163 | 0 | 752,713 | 26.7% |
| 2025-09-10 | 233,391 | 0 | 779,694 | 29.9% |
| 2025-09-09 | 268,171 | 400 | 774,546 | 34.6% |
| 2025-09-08 | 171,733 | 0 | 631,116 | 27.2% |
| 2025-09-05 | 196,183 | 0 | 1,076,636 | 18.2% |
| 2025-09-04 | 375,674 | 0 | 1,055,498 | 35.6% |
| 2025-09-03 | 361,342 | 0 | 1,713,477 | 21.1% |
| 2025-09-02 | 131,618 | 104 | 1,693,179 | 7.8% |
| 2025-08-29 | 788,937 | 0 | 1,711,346 | 46.1% |
| 2025-08-28 | 849,068 | 0 | 4,416,133 | 19.2% |
| 2025-08-27 | 153,736 | 801 | 673,551 | 22.8% |
| 2025-08-26 | 269,260 | 37,750 | 809,503 | 33.3% |
| 2025-08-25 | 457,745 | 0 | 2,720,675 | 16.8% |
| 2025-08-22 | 487,790 | 5,217 | 4,785,300 | 10.2% |
| 2025-08-21 | 556,839 | 23,255 | 1,759,040 | 31.7% |
| 2025-08-20 | 541,108 | 0 | 1,374,891 | 39.4% |
| 2025-08-19 | 405,578 | 0 | 1,385,843 | 29.3% |
| 2025-08-18 | 625,451 | 485 | 1,523,040 | 41.1% |
| 2025-08-15 | 1,026,870 | 1,603 | 3,288,877 | 31.2% |
| 2025-08-14 | 1,245,698 | 200 | 3,448,346 | 36.1% |
| 2025-08-13 | 790,054 | 0 | 4,585,039 | 17.2% |
| 2025-08-12 | 443,543 | 382 | 1,179,222 | 37.6% |
| 2025-08-11 | 336,135 | 0 | 1,321,629 | 25.4% |
| 2025-08-08 | 485,257 | 200 | 1,830,298 | 26.5% |
| 2025-08-07 | 801,273 | 5,630 | 4,409,964 | 18.2% |
| 2025-08-06 | 926,718 | 0 | 3,689,586 | 25.1% |
| 2025-08-05 | 811,116 | 0 | 2,559,415 | 31.7% |
| 2025-08-04 | 894,078 | 98,989 | 4,200,952 | 21.3% |
| 2025-08-01 | 1,671,900 | 54,693 | 12,502,189 | 13.4% |
| 2025-07-31 | 823,478 | 0 | 2,928,549 | 28.1% |
| 2025-07-30 | 1,135,025 | 2,358 | 4,670,483 | 24.3% |
| 2025-07-29 | 244,810 | 210 | 1,095,855 | 22.3% |
| 2025-07-28 | 387,786 | 2,407 | 1,088,254 | 35.6% |
| 2025-07-25 | 405,263 | 98,174 | 1,551,847 | 26.1% |
| 2025-07-24 | 587,916 | 33,192 | 2,074,221 | 28.3% |
| 2025-07-23 | 948,572 | 1,500 | 3,643,609 | 26.0% |
| 2025-07-22 | 410,824 | 400 | 1,505,845 | 27.3% |
| 2025-07-21 | 366,204 | 0 | 1,807,985 | 20.3% |
| 2025-07-18 | 374,765 | 0 | 1,763,186 | 21.3% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy